A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Recruiting · Phase 3 · NCT07219420
Conditions: Palmoplantar Pustulosis
At a glance
- Research payments reported, 2025
- $1,063
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 320
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Bimekizumab (drug), Placebo (drug)
- Dates
- Started 2025-11-14; completion 2029-11-22
- Results posted
- Not yet
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
From ClinicalTrials.gov, last updated 2026-08-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $1,063 in research payments for this study in 2025 (1 payments).
Products named: Bimzelx
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Driven Research Llc $1,063
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.